Baveno VII - Renewing consensus in portal hypertension.
Roberto de Franchis, Jaime Bosch, Guadalupe Garcia-Tsao...
https://pubmed.ncbi.nlm.nih.gov/35120736/Actively Recruiting
Led by Taipei Veterans General Hospital, Taiwan · Updated on 2025-02-11
80
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to compare the effectiveness of carvedilol combined with endoscopic variceal ligation EVL versus carvedilol alone in preventing the first esophageal variceal bleeding in patients with cirrhosis who do not respond to carvedilol. The study also seeks to learn about the safety of combining carvedilol with EVL and to explore differences in other gastrointestinal bleeding, liver complications, overall survival, adverse events, and tolerability between the two approaches. Participants will be randomly assigned to one of two groups one group will take carvedilol daily starting at 6.25 mg and increasing to 12.5 mg if tolerated, along with EVL procedures every 3 to 4 weeks until varices are eradicated, followed by regular endoscopic checkups the other group will take carvedilol alone with the same dosing schedule. The study is open-label and includes regular clinical visits and follow-ups according to protocol. During the study, participants will visit the clinic every 2 to 3 months for checkups and tests. They will keep a diary to record vital signs such as systolic and diastolic blood pressure and heart rate, as well as any symptoms. The main outcome measured is the occurrence of esophageal variceal bleeding over three years. Secondary outcomes include other upper gastrointestinal bleeding, liver decompensation events, overall survival, and adverse events. The study is sponsored by Taipei Veterans General Hospital, Taiwan.
CONDITIONS
Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders
T
Tsung-Chieh Yang, MD
M
Ming-Chih Hou, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Taipei Veterans General Hospital, Taiwan
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 years
Participants take carvedilol daily, starting from 6.25 mg per day and increasing to 12.5 mg per day if tolerated. Some participants also undergo endoscopic variceal ligation every 3-4 weeks until variceal eradication, followed by regular endoscopic follow-up according to the protocol.
Endoscopic variceal ligation every 3-4 weeks until variceal eradication, followed by regular endoscopic follow-up; daily medication intake
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Roberto de Franchis, Jaime Bosch, Guadalupe Garcia-Tsao...
https://pubmed.ncbi.nlm.nih.gov/35120736/Arun J Sanyal, Jaime Bosch, Andres Blei...
https://pubmed.ncbi.nlm.nih.gov/18471549/Jason M Ridlon, Joao Marcelo Alves, Phillip B Hylemon...
https://pubmed.ncbi.nlm.nih.gov/23851335/Mauro Giuffrè, Johannes Dupont, Alessia Visintin...
https://pubmed.ncbi.nlm.nih.gov/38664292/H B El-Serag, J E Everhart
https://pubmed.ncbi.nlm.nih.gov/11151893/C Merkel, M Bolognesi, D Sacerdoti...
https://pubmed.ncbi.nlm.nih.gov/11050041/Ankit Bhardwaj, Chandan Kumar Kedarisetty, Chitranshu Vashishtha...
https://pubmed.ncbi.nlm.nih.gov/27298379/Juan P Arab, Rosa M Martin-Mateos, Vijay H Shah
https://pubmed.ncbi.nlm.nih.gov/28550391/Mercedes Fernandez, Francesco Vizzutti, Juan Carlos Garcia-Pagan...
https://pubmed.ncbi.nlm.nih.gov/14988842/Lise Lotte Gluud, Aleksander Krag
https://pubmed.ncbi.nlm.nih.gov/22895942/Taipei Veterans General Hospital, Taiwan
Lead Sponsor